We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.51%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$201M
AUM Growth
-$42.4M
Cap. Flow
+$13M
Cap. Flow %
6.49%
Top 10 Hldgs %
47.8%
Holding
87
New
12
Increased
27
Reduced
14
Closed
4

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$4.12M
2
VKTX icon
Viking Therapeutics
VKTX
+$2.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$1.82M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.8M
5
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$1.46M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.9M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.46M
3
NVAX icon
Novavax
NVAX
+$1.32M
4
KURA icon
Kura Oncology
KURA
+$1.22M
5
IMDZ
Immune Design Corp.
IMDZ
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 88.58%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
51
Ardelyx
ARDX
$1.22B
$846K 0.42%
472,859
– –
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$10.8B
$744K 0.37%
+6,600
New +$1.02M
URGN icon
53
UroGen Pharma
URGN
$1.86B
$646K 0.32%
15,000
– –
SCYX icon
54
SCYNEXIS
SCYX
$48.1M
$613K 0.3%
15,912
– –
OBSV
55
DELISTED
ObsEva SA Ordinary Shares
OBSV
$561K 0.28%
44,338
+1,000
+2% +$14.9K
CDTX
56
DELISTED
Cidara Therapeutics
CDTX
$500K 0.25%
10,638
– –
SPRO icon
57
Spero Therapeutics
SPRO
$67.7M
$431K 0.21%
70,000
– –
VLRX
58
DELISTED
VALERITAS HOLDINGS INC
VLRX
$431K 0.21%
+66,250
New +$1.06M
ALDX icon
59
Aldeyra Therapeutics
ALDX
$92.9M
$415K 0.21%
+50,000
New +$512K
KALV
60
DELISTED
KalVista Pharmaceuticals
KALV
$399K 0.2%
20,225
+2,500
+14% +$50.3K
LRMR icon
61
Larimar Therapeutics
LRMR
$397M
$358K 0.18%
6,023
-1,131
-16% -$112K
CYPH
62
Cypherpunk Technologies Inc
CYPH
$62.9M
$340K 0.17%
17,000
+2,936
+21% +$129K
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
$338K 0.17%
20,500
– –
ARCT icon
64
Arcturus Therapeutics
ARCT
$164M
$330K 0.16%
+72,805
New +$448K
MASI
65
DELISTED
Masimo
MASI
$322K 0.16%
3,000
– –
ADXS
66
DELISTED
Advaxis Inc
ADXS
$317K 0.16%
111,111
– –
RIGL icon
67
Rigel Pharmaceuticals
RIGL
$681M
$316K 0.16%
13,760
– –
PHAS
68
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$309K 0.15%
+100,000
New +$396K
STRO icon
69
Sutro Biopharma
STRO
$401M
$284K 0.14%
3,149
+400
+15% +$48.3K
APTX
70
DELISTED
Aptinyx Inc. Common Stock
APTX
$240K 0.12%
14,500
– –
SLGL icon
71
Sol-Gel Technologies
SLGL
$269M
$211K 0.1%
3,500
– –
KA
72
DELISTED
Kineta, Inc. Common Stock
KA
$177K 0.09%
+390
New +$264K
NERV icon
73
Minerva Neurosciences
NERV
$185M
$176K 0.09%
3,261
-102
-3% -$7.47K
KDMN
74
DELISTED
Kadmon Holdings, Inc.
KDMN
$136K 0.07%
65,500
+2,500
+4% +$6.29K
LCTX icon
75
Lineage Cell Therapeutics
LCTX
$269M
$91K 0.05%
100,000
-14,300
-13% -$21.9K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, DAFNA Capital Management held 87 positions worth $201M, down 17% from $244M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $13M of net new capital in Q4 2018, opening 12 new positions and adding to 27 existing holdings. Its largest new stake was Viking Therapeutics: 179,200 shares worth $1.37M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.9M trimmed.

  • DAFNA Capital Management's largest Q4 2018 buy was Viking Therapeutics: 179,200 shares worth $1.37M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q4 2018, an estimated $4.12M increase.
  • DAFNA Capital Management's biggest Q4 2018 reduction was Immunomedics Inc, cutting an estimated $1.9M.
  • DAFNA Capital Management fully exited Novavax in Q4 2018, selling an estimated $1.32M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $201M portfolio in Q4 2018.
  • DAFNA Capital Management opened 12 new positions and closed 4 in Q4 2018.
  • DAFNA Capital Management's portfolio value fell 17% quarter-over-quarter to $201M.

Based on DAFNA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.